



arthritis and rheumatism

Official Journal of The American Rheumatism Association
Section of The Arthritis Foundation

VOLUME 14, 1971



Medical Department
HARPER & ROW, PUBLISHERS, INC.
New York

ARTHRITIS AND RHEUMATISM

EDITOR

Charles L. Christian, MD

EDITORIAL BOARD

K. Frank Austen, MD, Boston	Stephen M. Krane, MD, Boston
J. Claude Bennett, MD, Birmingham	Henry G. Kunkel, MD, New York
Alfred J. Bollet, MD, Augusta	Henry J. Mankin, MD, New York
John J. Calabro, MD, Worcester	Mart Mannik, MD, Seattle
Alan S. Cohen, MD, Boston	William M. O'Brien, MD, Charlottesville
Paul H. Curtiss, Jr, MD, Columbus	Gerald P. Rodnan, MD, Pittsburgh
John L. Decker, MD, Bethesda	John T. Sharp, MD, Houston
Edward C. Franklin, MD, New York	Leif B. Sorensen, MD, PhD, Chicago
David S. Howell, MD, Miami	Charles D. Tourtelotte, MD, Philadelphia
William H. Kammerer, MD, New York	Stanley L. Wallace, MD, New York
Nathan J. Zvaifler, MD, San Diego	
Ralph C. Williams, Jr, MD, Albuquerque	

COMMITTEE FOR THE PUBLICATION OF

Arthritis and Rheumatism

Alan S. Cohen, MD, Chairman, Boston	Carl M. Pearson, MD, Los Angeles
K. Frank Austen, MD, Boston	Stanley L. Wallace, MD, New York
John S. Davis, MD, Charlottesville	Ralph C. Williams, MD, Albuquerque

arthritis and rheumatism

Official Journal of The American Rheumatism Association
Section of The Arthritis Foundation

CONTENTS

No. 1 (January-February)

Antibodies to Viral Antigens in Systemic Lupus Erythematosus <i>F. Blaine Hollinger, John T. Sharp, Martin D. Lidsky and W. E. Rawls</i>	1
The Rarity of Ankylosing Spondylitis in the Black Race <i>John Baum and Morris Ziff</i>	12
Acute Arthritis Complicating Rubella Vaccination <i>George R. Thompson, Alfredo Ferreyra and Robert G. Brackett</i>	19
Anemia as a Presenting Manifestation of Giant Cell Arteritis <i>L. A. Healey and Kenneth R. Wilske</i>	27
Avoiding False-Positive Joint Scans by the Use of Labeled Albumins <i>Marvin B. Cohen and Arthur Lorber</i>	32
Connective Tissue Activation. I. The Nature, Specificity, Measurement and Distribution of Connective Tissue Activating Peptide <i>C. William Castor</i>	41
Connective Tissue Activation. II. Abnormalities of Cultured Rheumatoid Synovial Cells <i>C. William Castor</i>	55
Canine Rheumatoid Arthritis: A Case Report <i>Robert M. Lewis and Yves Borel</i>	67
A Rapid Method for Evaluating the Structure and Function of the Rheumatoid Hand <i>Paul S. Treuhaft, Marilyn R. Lewis and Daniel J. McCarty</i>	75
The Complement System in Rheumatoid Synovitis. II. Intracytoplasmic Inclusions of Immunoglobulins and Complement <i>Melvin C. Britton and Peter H. Schur</i>	87
Antibacterial Activity of Synovial Fluid During Therapy of Septic Arthritis <i>Richard H. Parker and Frank R. Schmid</i>	96
Rheumatoid Synovial Cyst of the Hip: A Case Report <i>Cecil Samuelson, John R. Ward and Dominic Albo</i>	105
Chronic Synovitis as a Manifestation of Calcium Crystal Deposition Disease <i>Roland W. Moskowitz, Benjamin K. Harris, Abraham Schwartz and Gerald Marshall</i>	109

A Study of Regenerated Synovium After Synovectomy of the Knee in Rheumatoid Arthritis

*Chitranjan S. Ranawat, Lee Ramsay Straub, Richard Freyberg,
Jose L. Granda and Marcos Rivelis* 117

Joint Lubrication with Artificial Lubricants

Eric L. Radin, Igor L. Paul and Paul A. Weisser 126

Communications

Treatment with Colchicine if the Periarticular Inflammation Associated with Sarcoidosis: A Need for Continued Appraisal

Edward D. Harris, Jr. and Michael Millis 130

Guidelines for the Use of Cytotoxic Drugs in Rheumatic Diseases

Robert S. Schwartz and James D. C. Gowans 134

Current Comments

Infection in Rheumatoid Arthritis *John Baum* 135

Polymyalgia Rheumatica and Giant Cell Arteritis

L. A. Healey, Frank Parker and Kenneth R. Wilske 138

Editorials

Arthritis and Rheumatism Jan-Feb 1971 142

Infection and Chronic Rheumatic Disease 143

Book Reviews

ARA News 144

Abstracts 145

146

No. 2 (March-April)

Mycoplasma Hyorhinis Swine Arthritis. I. Clinical and Microbiologic Features *Jerri A. Barden and John L. Decker* 193

Mycoplasma Hyorhinis Swine Arthritis. II. Morphologic Features

R. S. Ennis, D. Dalgard, J. T. Willerson, J. A. Barden and J. L. Decker 202

Intra-Articular Thiopeta in Rheumatoid Disease. A Clinical Analysis of 123 Injected MP and PIP Joints

Monty R. Ellison and Adrian E. Flatt 212

Levels of Three Hydrolases in Rheumatoid and Regenerated Synovium *J. L. Granda, C. S. Ranawat and A. S. Posner* 223

Hypocomplementemia in Rheumatoid Arthritis

Alejandro E. Franco and Peter H. Schur 231

Antinuclear Antibodies, Rheumatoid Factor and C-Reactive Protein in Serum of Normal Women Using Oral Contraceptives

Donald R. Kay, Giles G. Bole, Jr. and William J. Ledger 239

Factors Affecting Survivorship in Polymyositis. A Life-Table Study of 124 Patients

Thomas A. Medsger Jr., Harry Robinson and Alfonse T. Masi 249

The Release of DNA into Serum and Synovial Fluid

Graham R. V. Hughes, Selwyn A. Cohen, Robert W. Lightfoot Jr., Jay I. Meltzer and Charles L. Christian 259

Fibrinogen Degradation Products in Serum and Urine of Patients with Systemic Lupus Erythematosus. Relation to Renal Disease and Pathogenetic Mechanism <i>Bwogi R. Kanyerezi, Stephen K. Lwanga and Kurt J. Bloch</i>	267
Immunoglobulin G Subclasses of Antinuclear Antibodies and Renal Deposits. Comparison of Systemic Lupus Erythematosus, Drug-Induced Lupus and Rheumatoid Arthritis <i>Jovan N. Kacaki, Mary Lou Callerame, Stephen E. Blomgren and John H. Vaughan</i>	276
Hyperuricemia in American Samoans <i>L. A. Healey and Kenneth W. Jones</i>	283
Editorial	
Mycoplasmas	286
ARA News	289
Book Review	290

No. 3 (May-June)

Ankylosing Spondylitis and Spondylitis Accompanying Ulcerative Colitis, Regional Enteritis, Psoriasis and Reiter's Disease: A Comparative Study <i>Currier McEwen, Dominick DiTata, Clare Lingg, Anna Porini, Armine Good and Thomas Rankin</i>	291
The Human Fetal Synovium: Histology, Fine Structure and Changes in Organ Culture <i>Phoebe R. Krey, Alan S. Cohen, Charles B. Smith and Maxwell Finland</i>	319
Incidence of Antibodies to Double-Stranded RNA in Systemic Lupus Erythematosus and Related Diseases <i>Peter H. Schur, B. David Stollar, Alfred D. Steinberg and Norman Talal</i>	342
Navajo Arthritis—An Unusual, Acute, Self-Limited Disease <i>Albert L. Muggia, David A. Bennahum and Ralph C. Williams Jr.</i>	348
Response of Joints to Impact Loading: I. In Vitro Wear <i>Eric L. Radin and Igor L. Paul</i>	356
Communication	
Cooperating Clinics Committee <i>John L. Decker, L. Andrew Healey and William M. O'Brien</i>	363
Obituary	365
Abstracts	366
News of the Society	428

No. 4 (July-August)

Ultrastructural Studies of Renal Peritubular Amyloid Experimentally Induced in Guinea Pigs. II. Tubular Epithelial Cells <i>Alan S. Cohen and Tsuranobu Shirahama</i>	429
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----

7S_yM-globulin in Rheumatoid Arthritis: Evaluation of its Clinical Significance	<i>David E. Stage and Mari Mannik</i>	440
Amyloidosis: A Study of Its Pathogenesis and the Role of Humoral Immunity	<i>John L. Abruzzo</i>	451
Myoglobinemia and Myoglobinuria in Patients with Myositis	<i>Lawrence J. Kagen</i>	457
The Human Incudomalleal Joint: Chondroid Articular Cartilage and Degenerative Arthritis	<i>Ruth Gussen</i>	465
Synovial Fluid pH, Lactate, Oxygen and Carbon Dioxide Partial Pressure in Various Joint Diseases . . .	<i>Paul S. Treuhaft and Daniel J. McCarty</i>	475
Reactions of Systemic Lupus Erythematosus Sera with Histone Fractions and Histone-DNA Complexes	<i>B. David Stollar</i>	485
Scale Effects in Animal Joints. II. Thickness and Elasticity in the Deformability of Articular Cartilage	<i>William H. Simon</i>	493
Fibrinogen-Fibrin Breakdown Products in Pathologic Synovial Fluids: An Immunologic Study	<i>Johs. Gormsen, R. Bach Andersen and C. Feddersen</i>	503
Sequential Changes in Human Polymorphonuclear Leukocytes After Urate Crystal Phagocytosis: An Electron Microscopic Study	<i>H. Ralph Schumacher and Paulding Phelps</i>	513
Variations of Serum Concentrations and Half-Life of Salicylate in Patients with Rheumatoid Arthritis	<i>Harold E. Paulus, Mark Siegel, Edward Mongan, Ronald Okun and John J. Calabro</i>	527
The Effect of Chrysotherapy on Trace Metals in Patients with Rheumatoid Arthritis	<i>William Niedermeier, William W. Prillaman and James H. Griggs</i>	533
Glomerular Cytoplasmic Tubular Structures in Renal Biopsies of Patients with Systemic Lupus Erythematosus and Other Diseases	<i>Eric R. Hurd, Edwin Eigenbrodt, Howard Worthen, Stanley S. Strunk and Morris Ziff</i>	539
The Radiographic Pattern of Polyarthritis in Reiter's Syndrome	<i>Stephen D. Sholkoff, Morton G. Glickman and Howard L. Steinbach</i>	551
ARA News		556

No. 5 (September-October)

Gonococcal Arthritis in Two Patients with Active Lupus Erythematosus: A Diagnostic Problem	<i>John S. Edelen, Michael D. Lockshin and E. Carwile LeRoy</i>	557
Permeability of Human Synovial Membrane to Plasma Proteins: Relationship to Molecular Size and Inflammation	<i>Irving Kushner and Jo Anne Somerville</i>	560
Reciprocal Skin Grafts in Systemic Sclerosis (Scleroderma)	<i>James F. Fries, John E. Hoopes and Lawrence E. Shulman</i>	571

Juvenile Ankylosing Spondylitis	
<i>John R. Ladd, James T. Cassidy and William Martel</i>	579
Demonstration of Dissecting Popliteal Cysts by Joint Scans After Intra-Articular Isotope Injections	
<i>Melvin H. Levin, Robert A. Nordyke and James J. Ball</i>	591
Experimental Allergic Myositis in Rats	
<i>Graeme Morgan, J. B. Peter and Brian B. Newbould</i>	599
Plaque-Forming Cell Response in Rats Receiving Mycobacterial Adjuvant on Day Zero and SRBC on Day Four	
<i>A. B. Stanfield, C. A. L. Stephens, Jr., Yvonne R. Clark, Margaret T. Mazur and Helen V. Ratajczak</i>	610
Immunochemical Conditions Affecting the Measurement of DNA Antibodies Using Ammonium Sulfate Precipitation	
<i>Theodore Pincus</i>	623
In Vivo and In Vitro Responses to Autologous IgG in Patients with Rheumatoid Arthritis	
<i>Lorne A. Runge and John A. Mills</i>	631
Azathioprine in the Treatment of Systemic Lupus Erythematosus: A Controlled Study	
<i>Maurice Sztejnbock, Ann Stewart, Herbert Diamond and David Kaplan</i>	639
The Relationship between Radiologic Changes and Osteoporosis of the Hand in Rheumatoid Arthritis	
<i>Anders O. Bjelle and Bo E. Nilsson</i>	646
Observations on the Eosinophilia of Certain Patients with Rheumatoid Arthritis	
<i>R. J. Winchester, S. D. Litwin, D. Koffler and H. G. Kunkel</i>	650
ARA News	666
Book Reviews	667

No. 6 (November-December)

Effects of Colchicine on Collagenase in Cultures of Rheumatoid Synovium	
<i>Edward D. Harris, Jr. and Stephen M. Krane</i>	669
Immunologic Studies of Juvenile Rheumatoid Arthritis	
<i>Nicolas E. Bianco, Richard S. Panush, J. Sydney Stillman and Peter H. Schur</i>	685
Studies of Antilymphocyte Antisera Produced Against Normal and Rheumatoid Arthritis Lymphocytes	
<i>Ralph C. Williams, Jr., Jean D. Emmons and Gonzalo P. Astorga</i>	697
Methods of Scoring the Progression of Radiologic Changes in Rheumatoid Arthritis: Correlation of Radiologic, Clinical and Laboratory Abnormalities	
<i>John T. Sharp, Martin D. Lidsky, Lois C. Collins and June Moreland</i>	706
A Defect in the Renal Excretion of Uric Acid in Filipinos	
<i>L. A. Healey and Pelagia S. Bayani-Sioson</i>	721
Tetracycline in the Treatment of Rheumatoid Arthritis: A Double Blind Controlled Study	
<i>Martha Skinner, Edgar S. Cathcart, John A. Mills and Robert S. Pinals</i>	727

Direct Lysis of Lymphocytes by Complement in Patients with Systemic Lupus Erythematosus	<i>Peter Stastny and Morris Ziff</i>	733
Serum and Synovial Fluid IgG, IgA and IgM Antigammaglobulins in Rheumatoid Arthritis		
<i>Richard S. Panush, Nicolas E. Bianco and Peter H. Schur</i>	737	
Isoniazid Acetylation Rate and Development of Antinuclear Antibodies Upon Isoniazid Treatment		
<i>Donato Alarcón-Segovia, Eugenia Fishbein and Hilda Alcalá</i>	748	
Arthritis Rounds		
Reiter's Disease, Ankylosing Spondylitis and Rheumatoid Arthritis Occurring Within a Single Family	<i>Armin E. Good</i>	753
Discussion: William O'Brien, Denys K. Ford		763
A Short Note		
The Source of the Inter-Alpha Trypsin Inhibitor in Pathologic Hyaluronateprotein	<i>Alfred Becker and John Sandson</i>	764
Reiter's Syndrome in Children: A Case Report and Review	<i>George N. Lockie and Gene G. Hunder</i>	767
Current Comment		
Leukocyte "Sense Organs"	<i>Eric E. Carlson and Ronald P. Messner</i>	773
Communication		
Failure of Rumalon to Increase Sulfate Incorporation by Articular Chondrocytes in Monolayer Culture	<i>Charles J. Malemud and Leon Sokoloff</i>	779
Mycoplasma Hyorhinis Swine Arthritis	<i>John L. Decker and Jerri A. Barden</i>	781
Brief Communication		
Absence of Australia Antigen and Antibody in Patients with Rheumatic Diseases	<i>Richard S. Panush, Elliott Alpert and Peter H. Schur</i>	782
Cytoplastic Tubular Structures in Pigmented Villonodular Synovitis	<i>Zelma Molnar, Walter H. Stern and Gordon H. Stoltzner</i>	784
Editorial		
Tetracycline in RA	<i>Charles D. Tourtellotte</i>	788
Presidential Address		
Taking Steady Aim	<i>John H. Vaughan</i>	789
ARA News		795
Book Review		796
Author and Subject Index — 1971		797



A A A A A A A A A A A A A A A A A A A A A A

Art

Author Index

- Abrams NR: 384 (abstr)
Abruzzo JL: 146 (abstr), 366 (abstr), 451
Adams LE: 163 (abstr)
Agnello V: 147 (abstr)
Agudelo CA: 147 (abstr)
Alarcón-Segovia D: 367 (abstr), 748
Albo D: 105
Albright JA: 148 (abstr)
Alcalá Hilda: 748
Alpert E: 782
Altman RD: 367 (abstr)
Andersen RB: 503
Anderson LG: 368 (abstr)
Anderson TO: 369 (abstr)
Andrews R: 368 (abstr)
Aoki T: 174 (abstr)
Araujo F: 149 (abstr)
Asofsky R: 368 (abstr)
Astorga GP: 697
Athanasius P: 401 (abstr)
Atkins C: 148 (abstr)
Atoynatan T: 369 (abstr)
Atra E: 179 (abstr)
Aufrang OE: 418 (abstr)
Austen KF: 392 (abstr), 410 (abstr)
- Bach, GL: 369 (abstr)
Bailey JP Jr: 403 (abstr), 407 (abstr)
Ball, JJ: 591
Barden JA: 193, 202, 781
Barnett EV: 149 (abstr), 149 (abstr)
Bartfeld H: 369 (abstr)
Barth WF: 394 (abstr)
Bartholomew BA: 185 (abstr), 415 (abstr)
Batt MT: 161 (abstr)
Baum, J: 12, 135, 426 (abstr)
Bayani-Sioson PS: 721
Beardmore TD: 150 (abstr), 169 (abstr)
Beasley RP: 150 (abstr), 423 (abstr)
Becker A: 764
Beetham WP Jr: 419 (abstr)
Bell DA: 369 (abstr)
Benedek TG: 403 (abstr)
Bennahum DA: 348
Bennett PH: 384 (abstr)
Berney S: 151 (abstr), 370 (abstr)
Bernhard GC: 389 (abstr), 406 (abstr)
Bertine JR: 175 (abstr)
- Bhorade M: 369 (abstr)
Bianco NE: 178 (abstr), 370 (abstr), 685, 737
Bierer WF: 182 (abstr)
Biesiadecki TF: 150 (abstr)
Birtwell WM: 387 (abstr)
Bishko F: 151 (abstr), 370 (abstr), 392 (abstr)
Bitter F: 152 (abstr)
Bitter T: 152 (abstr)
Bjelle AO: 646
Blakely JA: 371 (abstr)
Bland JH: 151 (abstr), 152 (abstr)
Blechman WJ: 406 (abstr)
Bloch KJ: 267, 388 (abstr)
Blomgren SE: 276
Bluestone R: 371 (abstr), 374 (abstr)
Bole GG Jr: 189 (abstr), 239, 393 (abstr)
Bollet AJ: 144, 403 (abstr), 407 (abstr)
Borel Y: 67
Bovy, Ruth A: 172 (abstr)
Bowman Barbara J: 383 (abstr)
Brackett RG: 19
Branson-Geokas Barbara: 152 (abstr)
Briccetti AB: 372 (abstr)
Britton MC: 87
Brooke MH: 168 (abstr)
Brown EM: 188 (abstr)
Brown JC: 153 (abstr)
Brubaker LH: 372 (abstr)
Brunner Carolyn M: 373 (abstr)
Butler WT: 373 (abstr)
Bywaters EGL: 153 (abstr), 371 (abstr)
- Calabro JJ: 154 (abstr), 527
Callerame MaryLou: 276
Callis G: 419 (abstr), 420 (abstr)
Capra JD: 154 (abstr)
Cardin C: 179 (abstr)
Carlson EE: 773
Carney JA: 177 (abstr)
Cassidy JT: 579
Castor CW: 41, 55
Cathcart ES: 372 (abstr), 727
Champion D: 374 (abstr), 374 (abstr), 375 (abstr)
Chandler RW: 154 (abstr)
Chang CC: 172 (abstr)
Chase GR: 405 (abstr)
Chase S: 176 (abstr)
Cheng C: 375 (abstr)

AUTHOR INDEX

- Chrisman OD: 376 (abstr)
Christian CL: 180 (abstr), 259, 378 (abstr)
Chu AB: 183 (abstr)
Chu TJ: 416 (abstr)
Chused TM: 155 (abstr)
Clark Yvonne R: 610
Cobb J: 173 (abstr)
Cohen AS: 155 (abstr), 259, 319, 372 (abstr), 397 (abstr), 429
Cohen LD: 186 (abstr)
Cohen MB: 32
Cohen SH: 376 (abstr)
Cole BC: 422 (abstr)
Collins Lois C: 706
Colwell JA: 413 (abstr)
Comerford FR: 155 (abstr)
Conn D: 156 (abstr)
Cook Elizabeth H: 403 (abstr)
Cooke TD: 156 (abstr), 377 (abstr), 417 (abstr)
Cooper NR: 180 (abstr)
Cracchiolo Andrea III: 157 (abstr)
Craig CP: 390 (abstr)
Cruz-Santiago Susano de la: 397 (abstr)
Cummings NA: 157 (abstr), 368 (abstr)
- Dalgard D: 202
Damiano V: 160 (abstr)
David JR: 178 (abstr)
Davis JS IV: 161 (abstr), 373 (abstr), 377 (abstr), 388 (abstr)
Davis W: 176 (abstr)
DeBracco Maria: 378 (abstr)
Decker JL: 193, 202, 364, (abstr), 781
DeHoratius R: 378 (abstr)
DeJesus D: 158 (abstr)
DeLuque O: 187 (abstr)
Denko CW: 158 (abstr), 379 (abstr)
Deodhar S: 177 (abstr)
Deshmukh K: 176 (abstr)
Diamond H: 158 (abstr), 379 (abstr), 380 (abstr), 639
DiTata D: 291
Dorey LR: 159 (abstr)
Dorfman H: 400 (abstr)
Dorsteitz Emily L: 41, 55
Downey JA: 380 (abstr), 381 (abstr)
Dubois EL: 152 (abstr)
Dyck P: 156 (abstr)
- Edelsen JS: 557
Ehrlich GE: 376 (abstr), 381 (abstr)
Eigenbrodt E: 539
Ein D: 175 (abstr)
- Eisenberg JW: 147 (abstr)
Elbaor JE: 381 (abstr)
Ellison MR: 212
Emkey RD: 396 (abstr)
Emmons JD: 697
England JPS: 422 (abstr)
Englund, DW: 182 (abstr)
Ennis RS: 202
Epstein MJ: 152 (abstr)
Epstein WV: 159 (abstr), 382 (abstr)
Esterly J: 405 (abstr)
Evans AS: 160 (abstr)
- Farrington Edna: 381 (abstr)
Feddersen C: 503
Feldman Elaine: 379 (abstr)
Ferreira A: 19
Ferzoco Linda: 396 (abstr)
Fink C: 391 (abstr)
Finland M: 319
Fishbein Eugenia: 367 (abstr), 748
Flatt AE: 212
Fleischmajer R: 160 (abstr)
Fosdick WM: 161 (abstr), 364
Fox IH: 169 (abstr)
Fraga A: 405 (abstr)
Franco AE: 162 (abstr), 231, 382 (abstr)
Frewin DB: 380 (abstr)
Freyberg R: 117, 402 (abstr)
Fries JF: 396 (abstr), 571
Friou GJ: 148 (abstr), 152 (abstr)
Fudenberg HH: 400 (abstr), 404 (abstr)
- Gabel RM: 411 (abstr)
Garfield Jane W: 182 (abstr)
Garrett Martha A: 388 (abstr)
Gentry LO: 149 (abstr)
Gerber DA: 162 (abstr), 383 (abstr)
Gleich GJ: 389 (abstr)
Glenn EM: 383 (abstr)
Glick EN: 388 (abstr)
Glick JM: 163 (abstr)
Glickman MG: 551
Glueck CJ: 384 (abstr)
Godwin JT: 399 (abstr)
Gofton JP: 384 (abstr)
Goldberg LS: 157 (abstr), 399 (abstr)
Goldman JA: 163 (abstr), 384 (abstr)
Goldstein M: 151 (abstr)
Good A: 753
Good AE: 291, 385 (abstr)
Gordon DA: 419 (abstr)
Gormsen J: 503

AUTHOR INDEX

- Gottlieb NL: 164 (abstr), 385 (abstr), 386 (abstr)
Gowans JDC: 134
Granda JL: 117, 173 (abstr), 223, 402 (abstr)
Grayzel AI: 164 (abstr)
Green FA: 386 (abstr)
Griggs JH: 533
Groseth-Dittrich Marsha F: 419 (abstr), 420 (abstr)
Gross J: 388 (abstr)
Gussen Ruth: 465

Haberman E: 164 (abstr)
Haberman JoAnn: 387 (abstr)
Hahn BH: 165 (abstr), 387 (abstr)
Haïm Thérèse: 179 (abstr)
Halberstam D: 158 (abstr), 380 (abstr)
Hall AP: 382 (abstr)
Hamerman D: 183 (abstr)
Hanson V: 159 (abstr), 170 (abstr)
Harley Naomi: 392 (abstr)
Harper E: 388 (abstr)
Harris BK: 109
Harris ED Jr: 130, 669
Hartog M: 371 (abstr)
Hashimoto K: 421 (abstr)
Healey LA: 27, 138, 283, 364, 424 (abstr), 670, 721
Heimer R: 366 (abstr)
Herd JK: 165 (abstr), 177 (abstr)
Herman JH: 166 (abstr), 384 (abstr)
Hess Evelyn V: 163 (abstr), 166 (abstr)
Heuser Eva T: 170 (abstr)
Hielman JD: 425 (abstr)
Highton TC: 404 (abstr)
Holborow EJ: 153 (abstr)
Hollander JL: 188 (abstr), 416 (abstr)
Hollinger FB: 1
Hollingsworth JW: 166 (abstr)
Holt PJL: 371 (abstr)
Hoopes JE: 571
Horwitz DA: 373 (abstr), 388 (abstr)
Houpt JB: 167 (abstr)
Howard A: 374 (abstr), 374 (abstr)
Howell DS: 167 (abstr), 367 (abstr), 410 (abstr)
Huang Nancy N: 150 (abstr)
Hughes GRV: 259
Hunder GG: 389 (abstr), 767
Hunt M: 167 (abstr)
Hurd ER: 377 (abstr), 539
Hussey CV: 389 (abstr)
Hyton Martha B: 368 (abstr)

Irvin WS: 165 (abstr), 180 (abstr), 372 (abstr),
 390 (abstr), 405 (abstr)
Isaacson AS: 159 (abstr)

Ishmael WK: 390 (abstr)

Jacobs ME: 390 (abstr)
Janis R: 164 (abstr)
Jasin HE: 156 (abstr), 377 (abstr)
Jelenik Joan G: 403 (abstr)
Johns TR: 391 (abstr)
Johnson RL: 391 (abstr)
Jones KW: 283
Jones RE: 422 (abstr)
Joseph BS: 391 (abstr)
Jourdian GW: 393 (abstr)
Justh GO: 168 (abstr)

Kacaki JN: 276
Kagen LJ: 169 (abstr), 457
Kantor TG: 392 (abstr)
Kanyerezi BR: 267
Kaplan AP: 392 (abstr)
Kaplan D: 158 (abstr), 380 (abstr), 639
Kaplan H: 168 (abstr)
Kapusta MA: 393 (abstr)
Katz R: 171 (abstr)
Kauffman MS: 376 (abstr)
Kay AB: 392 (abstr)
Kay DR: 239, 393 (abstr)
Kelley WN: 150 (abstr), 169 (abstr), 181 (abstr)
King Elizabeth: 394 (abstr)
Kippen I: 190 (abstr)
Kirschbaum B: 152 (abstr)
Klinenberg JR: 190 (abstr), 394 (abstr)
Kluge Ronica M: 394 (abstr)
Koffler D: 147 (abstr), 650
Koga T: 395 (abstr), 395 (abstr), 408 (abstr)
Kolterman OG: 396 (abstr)
Kondon J: 148 (abstr)
Konen T: 179 (abstr)
Koster Karen G: 170 (abstr)
Krane SM: 396 (abstr), 669
Krey, Phoebe R: 319, 397 (abstr)
Krueger RC: 163 (abstr)
Kunkel HG: 147 (abstr), 650
Kushner I: 560

Ladd JR: 579
Laimans Marta: 413 (abstr)
Laks MM: 419 (abstr), 420 (abstr)
Lane JM: 170 (abstr)
Lanyi VF: 397 (abstr)
Lazarus R: 158 (abstr), 380 (abstr)
Leddy JP: 369 (abstr)
Leger WJ: 239
Leers WD: 409 (abstr)

AUTHOR INDEX

- Le Roy EC: 380 (abstr), 381 (abstr), 557
Levin MH: 591
Lewis Marilyn R: 75
Lewis RM: 67
Levy J: 171 (abstr)
Lidsky MD: 1, 373 (abstr), 706
Lies RB: 398 (abstr)
Lightfoot RW Jr: 259
Lindsley Carol B: 398 (abstr)
Lingg Claire: 291
Lippiello L: 400 (abstr)
Lischner H: 150 (abstr)
Litwin A: 163 (abstr)
Litwin SD: 650
Lochead JA: 171 (abstr)
Lockie GN: 767
Lockshin MD: 172 (abstr), 557
Lorber A: 32, 172 (abstr)
Lotke PA: 173 (abstr)
Louie JL: 399 (abstr)
Lwanga SK: 267
- Martel W: 579
Martens M: 176 (abstr)
MacKenzie MR: 400 (abstr)
Madruga JF: 167 (abstr)
Malawista SE: 175 (abstr), 425 (abstr)
Malemud CJ: 779
Mankin HJ: 400 (abstr)
Mannik M: 184 (abstr), 440
Marchisello PJ: 290
Marienfeld D: 405 (abstr)
Marin DD: 401 (abstr)
Marsh Joanne M: 401 (abstr)
Marshall G: 109
Martin JH: 387 (abstr)
Mascarenhas BR: 402 (abstr)
Masi AT: 154 (abstr), 174 (abstr), 249, 403 (abstr), 421 (abstr)
Mattoli Martha: 402 (abstr)
Mazur Margaret T: 610
McCarty DJ: 75, 173 (abstr), 188 (abstr), 189 (abstr), 475
McCoy JM: 399 (abstr)
McCrae CR: 186 (abstr)
McDevitt HO: 396 (abstr)
McDuffie F: 156 (abstr)
McEwen C: 291
McLean ME: 399 (abstr)
Meade Jean C: 169 (abstr)
Mealing HG Jr: 403 (abstr)
Medsgier TA Jr: 174 (abstr), 249, 403 (abstr)
Mellors RC: 174 (abstr)
- Meltzer JI: 259
Meltzer M: 392 (abstr)
Messner RP: 175 (abstr), 398 (abstr), 403 (abstr), 773
Michaeli D: 404 (abstr)
Mikulla JM: 424 (abstr)
Mills DM: 404 (abstr)
Mills JA: 631, 727
Mills K: 406 (abstr)
Mintz G: 405 (abstr)
Mitchell MS: 175 (abstr)
Mittal KK: 373 (abstr)
Molinari JA: 175 (abstr)
Molnar Zelma: 784
Mongan E: 375 (abstr), 527
Moreland June: 706
Morgan G: 599
Morris AD: 405 (abstr)
Moskowitz RW: 109, 176 (abstr)
Muggia AL: 348
Muller FJ: 167 (abstr)
Muirden KD: 406 (abstr)
Müller-Eberhard HJ: 410 (abstr)
Multz CV: 406 (abstr)
- Nandi PK: 181 (abstr)
Natali PG: 416 (abstr)
Natvig JB: 175 (abstr)
Nedwich A: 160 (abstr)
Newbould BB: 599
Nicholas JJ: 407 (abstr)
Niederman JC: 160 (abstr)
Niedermeier W: 533
Nilsson BE: 646
Nimni M: 176 (abstr)
Nordyke RA: 591
Nosheny SZ: 376 (abstr)
Novack SN: 408 (abstr)
- O'Brien WM: 364
O'Connor G: 151 (abstr), 152 (abstr)
O'Duffy JD: 177 (abstr)
Ogra PL: 177 (abstr)
Ogryzlo MA: 167 (abstr), 419 (abstr)
O'Hare Maureen B: 407 (abstr)
Okun R: 375 (abstr), 527
Osterland CK: 165 (abstr)
Owens Sally L: 407 (abstr)
- Pan Sylvia F: 407 (abstr)
Panush RS: 178 (abstr), 370 (abstr), 685, 737, 782
Parker F: 138
Parker RH: 96

AUTHOR INDEX

- Paul IL: 126, 356
Paulus HE: 178 (abstr), 375 (abstr), 527
Pearson C: 178 (abstr), 191 (abstr), 375 (abstr), 395 (abstr), 395 (abstr), 408 (abstr), 408 (abstr)
Peltier AP: 179 (abstr)
Percy JS: 401 (abstr)
Perry HM Jr: 165 (abstr)
Persellin RH: 375 (abstr)
Peter JB: 179 (abstr), 599
Petrescu A: 401 (abstr)
Petz LD: 180 (abstr)
Phelps P: 368 (abstr), 415 (abstr), 418 (abstr), 513
Phillips PE: 180 (abstr)
Finals RS: 667, 727
Pincus T: 623
Pita JC: 167 (abstr), 367 (abstr), 410 (abstr)
Platt D: 175 (abstr)
Plotz CM: 414 (abstr)
Pollock BH: 424 (abstr)
Porini Anna: 291
Posner AS: 223
Postlethwaite AE: 181 (abstr)
Preston TA: 385 (abstr)
Prillaman WW: 533
Pruzanski W: 409 (abstr), 419 (abstr)
- Quagliata F: 370 (abstr), 426 (abstr)
Quismorio FP: 148 (abstr), 152 (abstr)
Quismorio SP: 170 (abstr)
- Radin EL: 126, 186 (abstr), 356
Ranawat CS: 117, 223
Rankin T: 291
Ratajczak Helen V: 610
Rawls WE: 1
Rawson AJ: 416 (abstr)
Reading A: 374 (abstr)
Reaven GM: 396 (abstr)
Recart S: 404 (abstr)
Reichlin M: 402 (abstr)
Remington JS: 149 (abstr)
Restifo RA: 406 (abstr)
Rigby P: 383 (abstr)
Ritchie JC: 41, 55
Rivelis M: 117
Robinson DR: 181 (abstr)
Robinson H: 154 (abstr), 249, 403 (abstr)
Rocha Maria J: 413 (abstr)
Rocklin RE: 178 (abstr)
Rodnan GP: 168 (abstr), 403 (abstr), 407, (abstr), 425 (abstr)
Rommel FA: 375 (abstr)
Rossen RD: 373 (abstr)
- Roth SH: 182 (abstr)
Rothbard S: 409 (abstr)
Rothfield Naomi F: 160 (abstr), 182 (abstr)
Ruddy S: 410 (abstr)
Runge LA: 631
- Sammarco J: 176 (abstr)
Samuelson C: 105
Sandson J: 764
Sapolsky AI: 367 (abstr), 410 (abstr)
Sarkissian E: 375 (abstr)
Saville PD: 411 (abstr)
Sbarbaro JL: 188 (abstr)
Schaeffer WI: 151 (abstr)
Schaller Jane: 398 (abstr), 411 (abstr), 412 (abstr), 412 (abstr)
Scher I: 183 (abstr)
Schmid FR: 96, 407 (abstr), 413 (abstr)
Schmidt Marcia C: 394 (abstr)
Schumacher HR: 513
Schur PH: 87, 162 (abstr), 178 (abstr), 231, 370 (abstr) 685, 737, 782
Schwartz A: 109
Schwartz RS: 134
Schumacher HR: 147 (abstr)
Sharp GC: 165 (abstr), 180 (abstr), 405 (abstr)
Sharp JT: 1, 287, 373 (abstr), 706
Sherry RG: 390 (abstr)
Sheth N: 371 (abstr)
Shirahama T: 429
Shirai T: 174 (abstr)
Sholkoff SD: 551
Shulman LE: 571
Siegel M: 527
Silberschmidt Ruth: 152 (abstr)
Simon WH: 493
Singer JM: 183 (abstr)
Sisk CW: 387 (abstr)
Skinner M: 727
Smiley JD: 171 (abstr)
Smith CB: 319
Smith EM: 164 (abstr), 385 (abstr), 386 (abstr)
Smith Patricia M: 164 (abstr), 385 (abstr), 396 (abstr)
Smith Susan F: 41, 55
Smyth CJ: 415 (abstr)
Smythe HA: 371 (abstr), 384 (abstr), 413 (abstr), 419 (abstr)
Sokoloff L: 779
Sokolov J: 397 (abstr)
Solomon SD: 173 (abstr)
Somerville JoAnne: 560
Spiera H: 414 (abstr)

AUTHOR INDEX

- Stage D: 184 (abstr), 440
Stanfield AB: 610
Stastny P: 184 (abstr), 414 (abstr), 733
Steele AD: 415 (abstr)
Steigerwald JC: 185 (abstr)
Steinbach HL: 551
Steinberg AD: 187 (abstr), 342, 390 (abstr)
Steinberg, ME: 170 (abstr), 186 (abstr)
Steiner Paula: 384 (abstr)
Stempel K: 179 (abstr)
Stephens CAL Jr: 610
Stern M: 396 (abstr)
Stern WH: 784
Stevens J: 144
Stewart Ann: 639
Stiehm R: 171 (abstr)
Stillman JS: 178 (abstr), 370 (abstr), 685
Stollar BD: 342, 485
Stoltzner GH: 784
Stolzer BL: 424 (abstr)
Straub LR: 117
Strong JS: 415 (abstr)
Stroud RM: 378 (abstr)
Strunk SS: 539
Sun DCH: 182 (abstr)
Swann DA: 186 (abstr)
Sztejnbock M: 639
- Talal N: 155 (abstr), 187 (abstr), 342, 368 (abstr), 390 (abstr)
Tan EM: 416 (abstr)
Tan Margaret: 382 (abstr)
Tan RGB: 371 (abstr)
Tanaka A: 395 (abstr)
Tanzer ML: 187 (abstr)
Tapanes FJ: 416 (abstr)
Tateishi H: 417 (abstr)
Terasaki PI: 149 (abstr)
Thompson GR: 19
Tourtellotte CD: 150 (abstr), 387 (abstr), 788
Trend Beth: 420 (abstr)
Treuhhaft PS: 75, 188 (abstr), 475
Troup G: 398 (abstr)
Troyer H: 417 (abstr)
Turmail GA Jr: 404 (abstr)
Turner RH: 188 (abstr), 418 (abstr)
Tse Rose L: 418 (abstr)
- Urowitz MB: 419 (abstr)
Usher MS: 393 (abstr)
- Valle L: 405 (abstr)
- Vande Sande B: 191 (abstr), 395 (abstr), 408 (abstr)
Vasquez C: 419 (abstr)
Vaughan JH: 276, 369 (abstr), 789
Vavrik M: 371 (abstr)
von Baeyer E: 158 (abstr)
Vyden JK: 419 (abstr), 420 (abstr)
- Waismann J: 394 (abstr)
Wald N: 407 (abstr)
Walker Sara E: 189 (abstr)
Wallingford WR: 189 (abstr), 420 (abstr)
Wanger Nancy S: 421 (abstr)
Ward JR: 105, 422 (abstr)
Ward PA: 190 (abstr)
Wardlaw AC: 409 (abstr)
Warner N: 400 (abstr)
Watanabe M: 401 (abstr)
Watson RF: 409 (abstr)
Webb FWS: 422 (abstr)
Wedgwood RJ: 412 (abstr)
Weinberger H: 419 (abstr), 420 (abstr)
Weir DD: 423 (abstr)
Weisser PA: 126
Weissman G: 191 (abstr)
Whitehouse DJ: 191 (abstr)
Whitehouse MW: 190 (abstr), 191 (abstr)
Whorton E: 152 (abstr)
Wilde AH: 423 (abstr)
Willerson JT: 202
Williams RC Jr: 175 (abstr), 348, 378 (abstr), 697
Willkens RF: 150 (abstr), 423 (abstr)
Wilkins RF: 150 (abstr)
Wilske KR: 27, 138, 424 (abstr)
Winchester RJ: 147 (abstr), 650
Winklestein A: 424 (abstr), 425 (abstr)
Woessner JF: 410 (abstr)
Worthen H: 539
Wright DG: 425 (abstr)
- Yassinger S: 407 (abstr)
Yeaton R: 408 (abstr)
- Zane S: 406 (abstr)
Zarins A: 400 (abstr)
Ziff M: 156 (abstr), 171 (abstr), 184 (abstr), 377 (abstr), 391 (abstr), 414 (abstr), 417 (abstr), 539, 732
- Zivkovic M: 426 (abstr)
Zurier RB: 191 (abstr), 426 (abstr)
Zvaifler NJ: 190 (abstr), 427 (abstr)

Subject Index

- β -N-acetylglucosaminidase of skin, 184
Acetylsalicylic acid
 comparison with placebo in RA, 406
 effect on indomethacin serum levels, 375
Acromegalic arthropathy
 clinical, radiologic and histologic picture, 371
 growth hormone and salicylate effects on lesions, 374
Adjuvant arthritis
 antigen responsible for, 395
 correlation with delayed skin reactivity to Wax D, 395
 inhibition of, 191
 lymphoid cell distribution, 370
 plaque-forming cell response, 610-622
 Prostaglandin E, suppression of, 426
Agammaglobulinemia, congenital, sex linked in RA, 150
Alkylating agents (*See thiotapec, nitrogen mustard*)
Allergic encephalitis, inhibition of, 191
Allergic thyroiditis, inhibition of, 191
Allison-Ghormley's nodules in Mycoplasma-induced arthritis, 202-211
Allopurinol
 induced orotic aciduria and orotidinuria, 150
 effect on pyrimidine synthesis in cultured fibroblasts, 150, 169
American Rheumatism Association
 News of the Association, 145, 289, 428, 556, 666, 795
 proceedings of the Interim Scientific Session, January 8-9, 1971, 146-192
 proceedings of the Interim Scientific Session, Annual Scientific Meeting, June 14-15, 1971, 366-427
Amyloid, renal peritubular, induced experimentally, 429-439
Amyloidosis
 lymphocyte transformation, 372
 pathogenesis and humoral immunity, 146, 451-456
Anemia, hypoproliferative in giant cell arteritis, 27
Anergy
 lymphocyte-monocyte defect in, 399
 viruses induced, 390
Animal models
 adjuvant arthritis, 370, 610, 622
 amyloidosis in hamsters, 146
 autoimmune disease in NZB/NZW mice, 155
 diffuse pulmonary granulomas, 378
 gouty arthritis, 394
Mycoplasma arthritides, 422
Mycoplasma hyorhinis induced arthritis, 193-201, 202-211
NZB/BW mice, antigen uptake, 153
 osteoarthritis, 176
osteoporosis, 170
polymyositis, experimental allergic myositis, 599-609
rubella induced chronic arthritis, 165
Anionic detergents, denaturation of collagen, 180-181
Antibody activity of monovalent IgM, 400
Antibiotics in septic arthritis, 96-104
Antibody
 anti-RNA, inhibition by RNA, 187
 Australia antigen in RA, 782-783
 DNA, adoptive transfer, 155
 DNA, counter immunoelectrophoresis, 377
 DNA, Farr ammonium sulfate technic for, 623-630
 double stranded RNA in SLE, 342-347
 EB and other viral in SLE, 160
 incidence to denatured collagen in RA, 404
 lymphocytotoxic antibodies in SLE and RA, 149, 373-374
 lysosomal in SLE, 369
 measles, rubella, mumps, parainfluenza Type 1 and 2 in connective tissue diseases, 1
 precipitating, levels in hypocomplementemia, 231-237
 specificity and structure of IgG and IgM RF, 154
 vir antigen in RA, 154
Antigammaglobulin
 IgA, IgG and IgM in RA, 737-747
 serum and synovial fluid IgG, IgA and IgM in JRA, 685-696
 serum IgA and IgG in psoriatic arthritis, 416
Antigen
 aggregated human gammaglobulin uptake, 153
 Australia antigen, absence in RA, 782-783
 hepatitis associated Australia antigen in SLE, 367
 histocompatibility in RA, 398
 induced RA, local immunoglobulin and antibody synthesis, 156
 isotypic and allotypic, 175
 lysosomal in SLE, 369
 nuclear:
 cellular immunity to in SLE, 163
 immune responses to in SLE, 165, 368
 in RA, 416

- RNA reactive with SLE sera, 402**
- Antigen-induced arthritis, 186**
- Antiglobulin, elution from rheumatoid synovium, 157**
- Antilymphocyte antisera, 697-705**
- Antinuclear antibody**
development during Isoniazid therapy, 748-752
182
- elution from rheumatoid synovium, 157
- false-positive toxoplasma fluorescent antibody tests due to, 149
- IgG subclasses, 277-282
- in hypocomplementemia, 231-237
- oral contraceptives and, 239-248
- Anti-RNA antibodies, 187**
- Aortic insufficiency**
in ankylosing spondylitis, 385
in Reiter's syndrome, 178
- Apophyseal joints, involvement in spondylitis, 291-318**
- Arteritis**
Giant cell
anemia as presenting manifestation, 27
clinical manifestations of, 424
polymyalgia and, 138-141
- Autoantibodies in SLE, 180**
- Arthritis**
associated with inflammatory bowel disease, 398
complicating rubella vaccination, 19
congenital agammaglobulinemia in, 150
early clue to cancer, 154
gouty, animal model for, 394
induced rubella associated with, 177
Mycoplasma hyorhinis induced, 193-201
Navajo, 348-355
pneumococcal, joint calcification in, 394
presenting manifestation of malignancy in children, 412
Rubella-induced chronic, 164
thermography in, 387
tuberculosis, diagnostic features, 151
- Arthropathy, acromegalic, 371**
- Arthroplasty**
knee in JRA, 159
knee, venographic study, 376
metallic prosthesis, evaluation of, 188
- Australia antigen**
absence in RA, 782-783
in SLE, 367
- Autoimmune disease, low-dose cyclophosphamide in, 189**
- Avascular necrosis of femoral head, 163**
- Azathioprine**
combination with prednisone and AZ-PR, 387
double-blind crossover study, 419
in adult polymyositis, 405
in RA and SLE, 134
in SLE, 639-645
in steroid resistant patient, 405
- Bactericidal activity of RA sera and synovial fluid, 409**
- Behcet's disease, 177**
- Blood flow in RA**
effect of propranolol on, 420
- Bone**
erosions, 423
erosions, fusion and demineralization in hypocomplementemia, 231-237
fetal, release of calcium by synovial culture media, 396
mass, effects of diphosphonate EHDP, 170
- Book Reviews:**
Boyle JA: Clinical Rheumatology. *Rev by LA Healey, 668*
Clinical Rheumatology. Edited by M Mason, HLF Currey. *Rev by RS Pinals, 667*
Frankel VH, Burstein AH: Orthopaedic Biomechanics. *Rev by J Stevens, 144*
Lubrication and Wear in Joints. Edited by V Wright. *Rev by L Sokoloff, 796*
Sokoloff L: The Biology of Degenerative Joint Disease. *Rev by AJ Bollet, 144*
- Bronchiectasis in RA, 135-137**
- Bronchitis in RA, 135-137**
- Calcification, joint, in pneumococcal arthritis, 394**
- Calcium crystal deposition disease, 109-116**
- Calcium pyrophosphate dihydrate effect on phagolysosomes, 420**
- Calcium release from ^{45}Ca labeled fetal bone, 396**
- Cancer, arthritis as early clue to, 154**
- Carbohydrate metabolism in gout, 379**
- Cartilage**
articular, biochemical and metabolic abnormalities in osteoarthritis, 400
articular, permeability changes induced by proteolytic enzymes, 173
- Cathepsin-D in normal aging, 367, 411**
- chondroitin articular and degenerative arthritis, 464-474**
- effect of Rumalon on *in vitro* sulfate incorporation, 779-780**
- lesions, effect of growth hormone and salicylate on, 376**

SUBJECT INDEX

- mineral growth inhibitor, 168
narrowing, incidence in hypocomplementemia, 231-237
pannus-free, 417
persistent antigen in immunologically induced synovitis, 377
prostaglandins, essential fatty acids and ^{35}S incorporation, 379
response to impact loading, 356-362
thickness and elasticity in deformability, 493-502
- Cathepsin-D
in aging normal and osteoarthritic cartilage, 367
in rheumatoid and regenerated synovium, 223-230
subunit structure of multiple forms, 410
- Cell-mediated immunity
in SLE, 152, 369
mechanisms in relapsing polychondritis, 166
parameters of in scleroderma, 425
- Cephaloridine in septic arthritis, 96-104
- Chemotaxis
activity of Kallekrein for human neutrophils, 392-393
in SLE, Felty's syndrome and spondylitis, 426
leukocyte, modified by RF, 388
- Chloroquine, effect on lymphocyte cytotoxin, 179
- Chondrocytes
early changes in cartilage degeneration, 417
effect of Rumalon on sulfate incorporation, 779-780
- Chondromalacia, effect of growth hormone and salicylate on, 376
- Choroid plexus in SLE, 148
- Chromosome abnormalities in scleroderma, 407
- Chrysotherapy
 ^{196}Au myochrysine in gold excretion, 386
effect on trace metals, 533-538
gold excretion and clinical status in RA, 385
gold pharmacodynamics in RA, 392
tissue and fluid gold levels in RA, 164
- Coagulation changes in SLE, 389
- Colchicine
combination with dexamethasone in polycystic disease, 211-217
effect acid phosphatase release, 368
effect on lysosomal enzyme release, 368
effect on phagocytosis of starch and urate crystals, 189
inhibition of lysosomal enzyme release from rheumatoid synovium, 425
periarticular inflammation in sarcoidosis, 130-133
stimulation of collagenase release, 669-684
- Colitis
arthritis associated with ulcerative, 398
- spondylitis accompanying ulcerative, 291-318
- Collagen
aldehydes in distribution changes during maturation, 176
antibodies to in RA, 404
denaturation of by anionic detergents, 181
fibrodysplasia ossificans progressiva, 151
human tissue immunofluorescent studies, 409
intermolecular crosslinks, 187
- Collagenase
colchicine stimulation of release from rheumatoid synovium, 669-684
tadpole, 388
- Complement
C1 inhibition by gammaglobulin mediated phagocytosis, 403
C1 in synovial fluid, 378
C1q, different binding substances in SLE, 382
C1q, IgG protein-binding in SLE, 159
C1q, interference with RF agglutination, 375
C3 hypercatabolism in RA and SLE, 410
C3 leukotactic factors and cleaving enzymes in synovial fluid, 190
effect on DNA binding activity, 626
fixation of cryoprecipitable complexes in Felty's syndrome, 427
hemolytic in RA, 213-237
hemolytic and complement components in JRA, 370
levels in JRA, 370-371
low levels in RA, 162
lymphocyte lysis in SLE, 414, 733-736
role in immune and inflammatory responses, 773-776
serum and CSF levels in SLE, 180
system in rheumatoid synovitis, 87-95
- Complement-fixation with platelets in SLE, 184
- C3 cleaving enzyme, 190
- Connective tissue
activators:
abnormalities of cultured rheumatoid synovium, 55-66
CTAP, nature, specificity, measurement and distribution, 41-54
diseases, virus antibody studies in, 180-181
metabolism in health and disease, 394
- Contraceptives, oral, effect on antinuclear antibody, 239-248
- Cooperating Clinics Committee, 363-364
- Cortisol
exogenous activator induced unresponsiveness, 55-66

SUBJECT INDEX

- inhibition of lysosomal enzyme mobilization and release, 425
- Counter immunoelectrophoresis DNA and anti-DNA determinations, 377
- C-reactive protein effect of oral contraceptives, 239-248
- Cryoglobulins, 7S, site for cryoprecipitation, 157
- Cryoprecipitable complexes, complement fixing in Felty's syndrome, 427
- Cyclophosphamide immunologic response to, 415
in RA and SLE, 134, 161
in rheumatoid vasculitis, 414
in Wegener's granulomatosis, 408
low-dose therapy in RA and SLE, 189
lupus-like disease, 189
lymphocyte response to PHA, 424
- Cyst, rheumatoid synovial of hip, 105-108
- Cytotoxins in dermatomyositis and polymyositis, 391
in RA, 161
in RA and SLE, 134
joint fluid compared with lymphocyte produced cytotoxin, 179
- Degenerative joint disease elution of antiglobulin and antinuclear antibody, 157
long term treatment with Rumalon, 158
- Demineralization in hypocomplementemia, 231-237
- Dermatomyositis cytotoxins produced by, 391
survivorship, 249-258
- Detergents, anionic, denatured collagen, 180-181
- Dexamethasone inhibition of lymphocyte cytotoxins, 180
- Digital arteries, changes in scleroderma, 168
- Diphosphonate EHDP, effect on disuse osteoporosis and bone mass, 170
- Dislocation, congenital, of hip, 411
- Dissecting popliteal cysts, joint scans demonstrating, 591-598
- DNA denatured, in vitro tests for cellular immunity in SLE, 401
determination by routine electrophoresis, 377
- Farr ammonium sulfate technic, factors affecting, 623-630
- precipitation of complex with anti-DNA, 161
release during high dose corticosteroid therapy, 259-266
- Dysphagia, effect on survivorship in polymyositis, 239-248
- EB virus antibody titer in SLE, 160
- Editorials: Arthritis and Rheumatism, Jan-Feb 1971, 142
Infection and chronic rheumatic disease, 143
- Mycoplasmas, 286
- Tetracycline in RA, 788
- Encephalitis, allergic, inhibition of, 191
- Enteritis, regional arthritis associated with, 398
spondylitis accompanying, 291-318
- Enzymes hydrolytic in regenerated and rheumatoid synovium, 223-230
- lysosomal: effect of colchicine and indomethacin on release, 368
effect of CTAP on, 41-54
inhibition by Prostaglandin E₁, 191
mobilization and release inhibition by colchicine and cortisol, 425
proteolytic, effect on permeability of articular cartilage, 173
- Eosinophilia in RA, 650-665
- Erysipelas in swine, 193-201, 202-211
- Erysipelothrix insidiosa in swine erysipelas, 196-197, 202-211
- Erythromycin, antibacterial activity in synovial fluid, 96-104
- Esophagus, abnormalities in rheumatoid disease, 182
- Evaluation, functional of rheumatoid patient, 397
- Extractable nuclear antigen antibodies to, 403
modifications of NZB/NZW nephritis, 405
- Extraspinal arthritis in juvenile ankylosing spondylitis, 579-590
- Farr ammonium sulfate technic, conditions affecting, 623-630
- Fatty acids, incorporation into cartilage, 379
- Felty's syndrome chemotaxis in, 426
complement fixing cryoprecipitable complexes, 427
- Femoral head, idiopathic avascular necrosis, 163
- Femoroinguinal swelling in RA, 105-108
- Fetal bone, ⁴⁵Ca release, 396
- Fibrinolytic changes in SLE, 389
- Fibroblasts cultured, effect of allopurinol and oxypurinol on pyrimidine synthesis, 169
dermal in fibrodysplasia ossificans progressiva, 151
metabolic abnormalities in cultures, 55-64
- synovial and dermal responsiveness to CTAP, 41-54

SUBJECT INDEX

- Fibrodysplasia ossificans progressiva, 151, 152
Fibrosis, muscle biopsies in, 168
Filipinos, gout in, 721-726
Finger
 intra-articular Thiotepa in RA, 212-222
 joints involved in spondylitis, 291-318
5-Fluorouracil in antigen-induced arthritis, 196
Foot, radioisotope scintiscanning, 393
Functional evaluation of rheumatoid patient, 397
- β -Galactosidase in skin, 185
Gammaglobulin, levels in hypocomplementemia, 231-237
Glomerulonephritis of NZB/NZW mice and Gross leukemia virus, 174
Glucose uptake, CTAP induced, 41-54, 55-66
 β -Glucuronidase
 levels in synovium, 223-230
 release, colchicine and indomethacin, 368
 skin, 183
Glycoprotein, synthetic, immunologic studies, 175
Glycosaminoglycans in fibrodysplasia ossificans progressiva, 151, 152
Glycosyl amino acids, urinary, 393
Gold
 binding to RF, 172
 excretion in RA, 385
 excretion of labeled myochrysine, 386
 inhibition of gammaglobulin heat aggregation, 383
 metabolism, 402
 pharmacodynamics, 402
 tissue and fluid levels, 164
- Gout
 animal model, 394
 carbohydrate and lipid metabolism, 379
 colchicine in, 130-133
 indomethacin therapy, 415
 synovial membrane changes, 147
Granulomatous disease, lupus-like symptoms, 411
Growth hormone effect on cartilage, 376
- Hand
 method of scoring abnormalities, 706-713
 radiologic changes, 646-649
 structure and function, evaluation, 75-88
- Haptoglobin, in synovial effusions, 374
- Hemolytic complement levels in RA, 231-238
- Hemolytic plaque assay, 610-622
- Hepatitis-associated (Australia) antigen in SLE, 367
- Herpes zoster in RA, 135-137
- Hiatal hernia in rheumatoid disease, 182
- Hip
 congenital dislocation, 411
 degenerative joint disease, Rumalon in, 158
 osteoarthritis, biochemical and metabolic abnormalities, 400
 spondylitis, changes in, 291-318
 synovial cyst, 105-108
 total replacement, 418
- Histidine
 in RA, 162
 inhibition of gammaglobulin aggregation, 383
- Histocompatibility antigens in RA, 398
- Histone fractions and DNA complexes, reactions of in SLE, 485-492
- Hurler's syndrome, 165
- Hyaluronate synthesis in synovial culture, 41-54, 55-66
- Hyaluronateprotein, 183, 764-766
- Hydralazine-induced lupus, 165
- Hydrolases, synovial levels, 223-230
- Hydroxychloroquine, on lymphocyte cytotoxin, 179
- Hydroxylsinonorleucine, 187
- γ -Hydroxyphenylbutazone, biochemical properties, 190
- Hyperemia, effect of propranolol on, 420
- Hypergammaglobulinemia, 233
- Hyperlipoproteinemia
 prednisone therapy and, 396
- Type IV, musculoskeletal disorders, 384
- Hypermetabolism, polypeptide inducing, 41-54, 55-66
- Hypermobility syndrome, 407
- Hypersensitivity, delayed, 172
- Hypertriglyceridemia, 686
- Hyperuricemia
 American Samoans, 283-286
 in Filipinos, 721-726
 kidney adaptation to, 414
- Hypocomplementemia in RA, 162, 231
- Immune complexes
 interaction with RF, 413
 role in humoral antibody responses, 153
- Immunity, cellular
 and IgA deficiency in JRA, 178
 in SLE, 152
 in vitro testing in SLE, 401
 to nuclear antigen in SLE, 163
- Immunoelectrophoresis, counter, 377
- Immunofluorescence
 human tissue collagen, 409
 joint fluid leukocytes, 87-95

- Immunoglobulin**
 aminoacid sequence of monoclonal IgG and M RF, 154
 deposition in synovial fluid leukocytes, 87-95
 detection of RF by immunofluorescence, 179
 E, levels in RA, 389
 IgG aggregates in serum and synovial fluid, 366
 IgG and cellular immunity, in JRA, 178
 IgG and IgM ratios in serum and synovial fluid, 560-570
 IgG and IgM in eosinophilia in RA, 650-665
 IgG paraproteinemia in multiple myeloma, 369
 IgG protein binding Clq in SLE, 159
 IgG, responses to in RA, 631
 7S IgM in RA with vasculitis, 184
 isotypic and allotypic antigens, 175
 local and specific antibody synthesis, 156
 monoclonal IgM anti-antibody activity, 400
 prolonged synthesis by rheumatoid synovium, 171
 RF precipitation of DNA-anti-DNA, 161
 role in immune and inflammatory responses, 773-778
 tissue fixed in SLE, 421
 Immunologic reactions in RA, 631-638
 Immunosuppressive therapy in NZB/NZW mice, 387
 Impact loading, response of joints, 357-362
 Incudomalleal joint, 465-474
 Indomethacin
 aspirin effect on serum levels, 375
 double-blind study with BLR-743, 415
 effect on acid phosphatase release, 368
 lysosomal enzyme release from PMN's, 368
Infection
 in RA, 135-137
 recurrent, lymphocyte-monocyte defect in, 399
 viral in RA, 155
Inflammation
 animal model, 370, 610
 Cathepsin-D levels as index of, 223-230
 joint, colchicine in, 130-138
 method of scoring in RA, 706-713
 Inter- α -trypsin inhibitor, 764-766
 Iodipamide, uricosuric effect of, 181
 Iopanoic acid, uricosuric effect of, 181
 Ipodate, uricosuric effect, 181
 Isoniazid
 acetylation rate and ANA development, 748-752
 induction of antinuclear antibodies, 182
 Isotopes in demonstrating dissecting popliteal cysts, 591-598
 Jaccoud's syndrome, anatomic changes, 153
 Joint
 artificial lubricants, 126-128
 calcification in pneumococcal arthritis, 394
 disease, synovial fluid pH, lactate, pO₂ and pCO₂, 188, 475
 hypermobility syndrome, 407
 inflammation, colchicine in, 130-133
 involvement in spondylitis, 291-318
 polyarthritis in Navajo arthritis, 348-355
 radioisotope scintiscanning, 393
 response to impact loading, 356-362
 scale effects in animals, 493-502
 size and inflammation in RA, 212-222
Juvenile rheumatoid arthritis
 antibody to double-stranded RNA, 342-347
 differentiation from juvenile ankylosing spondylitis, 579-590
 elution of antigen-globulin and antinuclear antibody from synovium, 157
 IgA deficiency and cellular immunity, 178
 immunologic studies, 685-696
 knee arthroplasty, 159
 serum and synovial fluid complement levels, 370-371
 single disease, 412
 synovectomy of hip, 148
 viral antibody in, 180
Kallikrein, chemotactic activity for human neutrophil, 392-393
Keratoconjunctivitis sicca, 407
Kidney
 adaptation to hyperuricemia, 414
 disease, fibrinogen degradation, 267-275
 handling of uric acid, 380
 IgG subclass deposits in SLE, 266-282
 impaired function, methotrexate therapy despite, 175
 lupus-like disease, cyclophosphamide in, 189
 transplant, serologic changes, 259-266
 uric acid excretion defect, 721-726
Knee
 arthroplasty, venographic study, 376
 involvement in spondylitis, 291-318
 metallic prosthetic arthroplasty, 188
 Navajo arthritis, 348
 regenerated synovium, 117-125
Lactate, CTAP induced increase, 41-54, 55-66
Lactic dehydrogenase, effect of colchicine and indomethacin on release, 368
Latex agglutination quantitation, 183

SUBJECT INDEX

- Latex test**
positive tests in hypocomplementemia, 231-237
synovial fluid inhibition of, 374
- Lesch-Nyhan syndrome**, allopurinol on pyrimidine excretion, 150
- Leukemia**
arthritis as presenting manifestation, 412
Gross, and glomerulonephritis, 174
- Leukocytes**
chemotaxis modified by RF, 388
chronic granulomatous disease, 411
immunoglobulin and complement deposition, 87-95
lysosomal antigens in SLE, 369
lysosomal enzyme release, colchicine and indomethacin on, 368, 425
phagocytic effect of colchicine and indomethacin, 388
prostaglandin E₁ inhibition of lysosomal enzyme release, 191
purine and pyrimidine analogues on motility, 418
"sense organs," 773-778
- Leukopenia in rabbits**, 166
- Lincomycin in septic arthritis**, 96-104
- Lipids**
metabolism in gout, 379
metabolism in RA, 396
- Lipoprotein, erythrocyte membrane and Rh antigen activity**, 386
- Lubricants for joints**, 126-128
- Lupus erythematosus**, lysosomal enzymes in skin, 185
- Lymphocytes**
antilymphocyte antisera, 697-705
complement lysis in SLE, 414, 733-736
cytotoxins, 179
monocyte defect in anergy, 399
response to PHA during cyclophosphamide, 424
role in immune and inflammatory responses, 773-778
transformation in amyloidosis, 372
- Lymphocytotoxic antibodies in RA, SLE**, 149
- Lymphoid cells in adjuvant arthritis**, 370
- Lymphoid tissue antigen concentration**, 153
- Lysinonorleucine**, 187
- Lysosomal enzymes**
colchicine and indomethacin effect on release, 368
in skin, 185
- β -Mannosidase of skin**, 185
- Manubriosternal articulation in spondylitis**, 291-318
- Meachim's scarification**, 376
- Metabolism**
abnormal in osteoarthritic cartilage, 400
- gold in RA, 402
- lipid**
in gout, 379
in rheumatic disease, 396
- Methotrexate**
combined with cytotoxic drugs in RA, 161
in disseminated vasculitis, 175
- Methyl cellulose**, joint lubricating properties, 126-129
- Monoclonal IgM anti-antibody**, 400
- Monocytes, in anergy**, 399
- Monosodium urate**, phagolysosome rupture, 420
- Mortality in infection in RA**, 135-137
- Multiple myeloma**
antibody to double-strand RNA, 342-347
RF of different species specificities, 369
- Muscle biopsy in rheumatic diseases**, 168
- Musculoskeletal disorders, hyperlipoproteinemia in**, 383
- Myasthenia gravis**
antibody to double strand RNA, 342-347
nonthymomatous recurrence of thymus, 391
- Mycobacterium butyricum**, plaque-forming cell response, 610-622
- Mycoplasma arthritides**, 427
- Mycoplasma hyorhinis swine arthritis**
clinical and microbiologic features, 193-201
metabolic inhibition test, 119
morphologic features, 202-211
mycoplasmas in arthritis, 287
- Myochrysine in gold excretion evaluation**, 386
- Myoglobinemia in myositis syndromes**, 169
- Myositis, allergic, experimental in rats**, 599-609
- Myositis syndromes, myoglobinemia and myoglobinuria in**, 169
- Nafcillin in septic arthritis**, 96-104
- Navajo arthritis**, 348-355
- Nephritis**
gouty, animal model, 394
lupus:
histology and clinical course, 170
IgG antinuclear antibody subclass deposits, 266-282
serologic changes during kidney transplant, 259-266
- NZB, intraglomerular deposits**, 155
- NZB/NZW modification by extractable nuclear antigen**, 405
- Neuropathy, rheumatoid, sural nerve biopsies**, 156
- Neutropenia in RA**, 372
- Neutrophils, chemotactic activity**, 392-393
- Nitrogen mustard in rheumatic disease**, 212

- Nodules, in hypocomplementemia, 231-237
 Nuclear ribonucleoprotein reactive, 402
- Oligoarthritis in juvenile ankylosing spondylitis, 579-590
 Orotic aciduria, allopurinol induced, 150
 Orotidinuria, allopurinol induced, 150
 Osteoarthritis
 Cathepsin D in cartilage, 367
 experimentally induced, 176
 haptoglobin in synovial effusions, 374
 hip, cartilage abnormalities, 400
 hydrolytic activity in synovium, 223-230
 inflammatory, 381
 multiple systems complaints, 390
 serum and synovial fluid protein levels, 560-570
 Osteophytes in spondylitis with other diseases, 291-318
 Osteoporosis
 disuse, diphosphonate EHDP in, 170
 hand, radiologic changes, 646-649
 spondylitis and, 291-318
 Oxonate, inhibition of uricase, 394
 Oxyphenylbutazone, biochemical properties, 190
 Oxyuripurinol, pyrimidine synthesis and, 169
- Painful foot, radioisotope scintiscanning, 392-393
 Pannus-free cartilage, EM study, 417
 Paramyxovirus-like structures in SLE, 421
 Paraproteinemia IgG, 369
 Parathyroid extract, effect on excretion of connective tissue components, 152
 Paravertebral ligamentous ossification, 291-318
 Parotid gland saliva studies, 407
 Pelvic whiskering, 291-318
 Penicillamine inhibition of gammaglobulin aggregation, 383
 Penicillin G, synovial fluid antibacterial activity, 96-104
 Periarticular inflammation, colchicine therapy, 130-133
 Pericarditis, rheumatoid, 382
 Pertechnetate^{99m} Tc, scanning arthritis joints, 32-40
 Phagocytic function in RA, 171
 Phagocytosis
 effect of colchicine on, 189
 IgG mediated by Cl, 403
 Phagosomes, 87-95
 Phagolysosome, 420
 Phenoxymethyl penicillin in septic arthritis, 96-104
 Phenylbutazone metabolites, properties, 190
- Phosphatase, acid
 release, effect of colchicine and indomethacin on, 368
 levels in synovium, 223-230
 Photometric automated technic for detecting and quantitating latex agglutination, 183
 Photoscanning
 ¹³¹I human serum albumin, ^{99m}Tc albumin or ^{99m}Tc pertechnetate, 32-40
 Pigmented villonodular synovitis, 784-787
 Pin distraction, silastic membrane for knee arthroplasty, 159
 Platelets, sulphapyrazone effect on survival, 371
 Pleural effusion, soluble DNA complexes, 416
 Pleuritis, acute flare in hypocomplementemia, 231-237
 Pleuropericarditis in RA, 650-665
 Pneumococcal arthritis, 394
 Pneumonitis in polymyositis, 239-248
 Polyarthritides
 in Navajo arthritis, 348-355
 mycoplasma hyorhinis induced in swine, 199-201
 radiographic pattern in Reiter's syndrome, 551-555
 Polychondritis, relapsing, immunopathology, 166
 Poly I - Poly C diminished adjuvant response, 390
 Polymyalgia rheumatica
 giant cell arteritis and, 138-141
 muscle biopsies in, 168
 Polymyositis
 cytotoxins, 391
 factors affecting survivorship, 249-258
 immunosuppressive therapy, 405
 Polypeptide
 connective tissue activating, 41-54, 55-66
 Polyvinyl pyrrolidine, joint lubrication, 126-129
 Prednisolone, effect of lymphocytic cytotoxins, 180
 Prednisone
 combination with AZ-PR and azathioprine, 389
 hyperlipoproteinemia, 396
 Presidential address, 789-794
 Prestyloid recess, 422
 Progressive systemic sclerosis (*See scleroderma*)
 Propranolol, peripheral hemodynamics, 420
 Prostaglandins
 E₁, inhibition of lysosomal enzymes, 191
 E₁, suppression of adjuvant arthritis, 426
 incorporation into cartilage, 379
 Protein IgG in SLE binding Clq, 159
 Protein polysaccharide
 immunologic nature of, 175
 role of aggregates in mineral growth, 167

SUBJECT INDEX

- Pseudogout, indomethacin and BLR-743 in, double-blind study, 415
- Psoriasis**
lysosomal enzymes of skin, 185
spondylitis accompanying, 291-318
- Psoriatic arthritis, serum anti-immunoglobulins, 416**
- Pulmonary fibrosis in RA, 650-665**
- Pulmonary granulomas, inflammation potentiation, by RF, 378**
- Pulmonary infiltration and survival in polymyositis, 239-248**
- Purine analogues, effect on PMN motility, 418**
- Puromycin, effect on lymphocyte cytotoxins, 179**
- Pyrimidine**
allopurinol and oxypurinol effects on cultured fibroblasts, 169
allopurinol inhibition of biosynthesis, 150
effect of analogues on PMN motility, 418
- Pyrophosphate, inorganic, levels in synovial fluid, 173**
- Radiologic changes in RA, scoring, 706-713**
- Raynaud's syndrome**
effect of reserpine on vasoconstriction, 381
vascular sensitivity to cold, 380
- Reiter's syndrome**
aortic insufficiency, 178
in children, 767-772
in RA, 753-764
radiographic pattern of polyarthritis, 551-555
spondylitis accompanying, 291-318
viral antibody studies, 180
- Renal excretion of uric acid, 158**
- Reserpine in Raynaud's syndrome and scleroderma, 381**
- Reticular cell sarcoma, arthritis in, 412**
- Rh antigen and membrane lipoprotein, 386**
- Rheumatic disease**
absence of Australia antigen and antibody, 782-783
functional evaluation, 397
lysosomal glycosidase in skin, 185
- Rheumatoid arthritis**
antibodies to denatured collagen, 404
antibody to double-strand RNA, 342-347
antilymphocyte antisera, 697-705
aspirin compared with placebo, 406
¹⁰⁶Au-labeled myochrysine in gold excretion study, 386
autologous IgG in immunologic reactions, 631-638
azathioprine, double-blind crossover study, 419
bacteriolytic and bactericidal activity, 409
canine, 672-676
- combined cytotoxic therapy, 161
complexes in pleural effusions, 416
cytotoxic drug therapy guidelines, 134
dissecting popliteal cysts, 591-598
- EM study of pannus-free cartilage, 417**
- eosinophilia in, 659-665**
- esophageal abnormalities, 182**
- femoroinguinal swelling, 105-108**
- fibrinogen degradation products, 267-275**
- gold excretion and clinical status, 385**
- gold levels in tissue and fluid, 164**
- gold metabolism, 402**
- gold pharmacodynamics, 392**
- haptoglobin in synovial effusions, 374**
- histidine, oral, in, 162**
- histocompatibility antigen in, 398**
- hypocomplementemia in, 162**
- IgG aggregates, 366**
- IgG levels, 389**
- IgG subclasses and renal deposits, 276-282**
- 7S IgM, 184**
- immunologic response to cyclophosphamide, 415**
- infection in, 135-137, 143**
- inflammation, serum: synovial fluid protein concentrations, 560-570**
- intra-articular C3 hypercatabolism, 410**
- intra-articular radioactive yttrium, 399**
- intra-articular thiopeta, 212-222**
- leukocyte immunoglobulin and complement, 87-95**
- local immunoglobulin and antibody synthesis, 156**
- low dose cyclophosphamide, 189**
- lymphocytotoxic antibodies, 149**
- metabolic abnormalities in cultured cells, 55-66**
- morphology of synovium favoring vasculitis, 401**
- muscle biopsies, 168**
- neuropathy, sural biopsy in, 156**
- neutropenia, 372**
- pericarditis, 382**
- peripheral hemodynamics, 419**
- phagocytic activity, 171**
- prevalence in Yakima Indians, 150**
- radiologic changes and osteoporosis of hand, 646-649**
- regenerated synovium after synovectomy, 117-125**
- Reiter's disease and ankylosing spondylitis associated with, 753-763**
- scoring osseous defects and joint space narrowing, 706-713**
- serum and synovial fluid anti-IgG, IgA and IgM, 416**
- subchondral plate defects and bone erosions, 423**
- synovial tissue and joint damage, 406**

- tetracycline therapy, 727-731
 thermography, 387
 treatment performance, 423
 triamcinolone hexacetonide intra-articularly, 383
 tryptophan metabolism, 167
 serologic investigations for infectious etiology, 154
 structure and function of hand, rapid evaluation, 75-86
 synovium, antiglobulin and antinuclear antibody elution, 157
 viral antibody studies, 180
- Rheumatoid factor
 agglutination test, interference by C1q, 375
 amino acid sequence in monoclonal IgG and IgM, 154
 binding of gold to, 172
 in eosinophilia, 650-665
 inhibition of latex test by synovial fluid, 374
 inhibition of red cell aggregation by nonsteroids, 383
 interaction with immune complexes, 413
 leukocyte chemotaxis modified by, 388
 oral contraceptives and, 239-248
 potentiation of pulmonary inflammatory response, 378
 precipitation of DNA and anti-DNA in SLE, 161
 production by rheumatoid synovium, quantitation, 171
 serum, detection by immunofluorescence, 179
 significance in SLE, 147
 specificity, molecular size and IgG paraproteinemia, 369
 synthesis by salivary gland in Sjogren's syndrome, 368
- Ribonucleic acids
 antibodies in hypocomplementemia, 231-237
 double stranded, antibodies to in SLE, 187, 342-347
 inhibition of anti-RNA antibodies by, 187
- Ribonucleoprotein antigen, 402
- Rubella
 acute arthritis complicating, 19
 antibody in SLE, 1
 arthritis in induced infection, 177
 virus induced chronic arthritis, 164
- Rumalon, sulfate incorporation by cartilage, 779-780
- Sabin-Feldman dye test, 149
- Sacroiliac
 arthritis in juvenile ankylosing spondylitis, 579-590
 involvement in spondylitis, 291-318
- Salicylate
 effect on cartilage lesions, 376
 effect on mobilization and release of lysosomal enzymes, 425
 serum levels and half-life, 527-532
- Saliva, parotid, in keratoconjunctivitis sicca, 407
- Salivary gland, synthesis of RF in Sjogren's syndrome, 368
- Sarcoidosis, colchicine in, 130-133
- Sarcoma, reticular cell, arthritis in, 412
- Scale effects in animal joints, 493-502
- Scintiscanning, in painful feet diagnosis, 393
- Scleroderma
 cellular immunity, 425
 chromosome abnormalities, 407
 effect of reserpine in, 371
 effect on survivorship in polymyositis, 239-248
 epidemiology, 174
 morphologic abnormalities of digital artery, 168
 reciprocal skin transplantation, 571-578
 subcutaneous tissue, 160
 survivorship factors, 403
 systemic, leg ulcers in, 419
 tryptophan metabolism, 167
 xylosylserine levels in urine, 393-394
- Septic arthritis
 antibacterial activity of synovial fluid during therapy, 96-104
 pneumococcal, 394
- Serology, infectious etiology in early RA, 154
- Shoulder, joint involvement in spondylitis, 291-318
- Silastic membrane, knee arthroplasty, 159
- Silicone fluid joint lubricating properties, 126-129
- Sjogren's syndrome
 antibody to double-stranded RNA, 342-347
 clinical and laboratory studies, 152
 RF synthesis by salivary gland tissue, 368
 Skin, lysosomal enzymes, 185
- Spine in spondylitis, 291-318
- Splenic germinal centers, localization of altered IgG, 153
- Spondylitis, ankylosing
 chemotaxis in, 426
 heart disease of, 384
 in North American Indian males, 384
 in various diseases, 291-318
 juvenile, 579-590
 rarity in black race, 13
 Reiter's disease and RA, 753-768
- Steroid therapy
 effect on survivorship in polymyositis, 239-248
 delayed hypersensitivity in guinea pigs, 172
 eosinophilia in RA, 650-665

SUBJECT INDEX

- intra-articular triamcinolone hexacetonide, 383
polymyalgia rheumatica and giant cell arteritis, 172
release of DNA into serum, 259-266
Structure and function of hand, rapid evaluation, 75-88
Subchondral plate defects, 423
Subcutaneous tissue in scleroderma, 160
Sulphinypyrazone, effects on survival, 371
Symphysis pubic involvement in spondylitis, 291-318
Syndesmophytes in spondylitis, 291-318
Synovectomy
 hip in JRA, 148
 hydrolytic activity in regenerated synovium, 223-290
 regenerated synovium of knee, 117-125
Synovial cyst of hip, 105-108
Synovial fluid
 antibacterial activity in septic arthritis, 96-104
 antibody levels in *Mycoplasma hyorhinis* arthritis, 193-201
 anti-IgA, IgG, IgM in JRA, 695-696, 737-747
 bactericidal and bacteriolytic activity, 409
 complement levels in JRA, 370-371
 Cl in, 378
 cytotoxins in, 179
 haptoglobin in RA, 374
 hyaluronate protein in, 764-766
 IgE levels in RA, 389
 IgG aggregates in RA, 366
 inhibition of RF latex test, 374
 in *Mycoplasma hyorhinis* induced arthritis, 202-211
 inorganic pyrophosphate levels, 173
 joint lubricant, 126-128
 leukotactic C3 factor and cleaving enzyme, 190
 low C levels in hypocomplementemia, 231-237
 pH, lactate, pO_2 and pCO_2 , in joint disease, 188, 475
RF in synovitis, 87-95
Synovitis
 chronic in calcium crystal deposition disease, 109-116
 complement system in, 87
 immunologically induced, 377
 intra-articular thiopeta for, 212-222
 intra-articular triamcinolone hexacetonide, 383-384
 intracellular inclusions of immunoglobulin and complement, 87-95
 pathogenesis, 150
 rubella induced, 164
 villonodular, cytoplasmic tubular structures, 784-787
Synovium
 acute gouty arthritis, study of, 147
 characteristics in RA, culture, 171
 culture medium, 396
 effect of colchicine on cultures, 669
 effect of radioactive colloid on, 404
 elution of antigen and antinuclear antibody, 157
EM analysis of cultured cells, 397
human fetal, histology, structure and changes, 319-341
lubrication of, 186
metabolic abnormalities in culture, 55-66
morphology favoring vasculitis, 401
myxovirus-like structures in pigmented villonodular, 784-787
pathology in mycoplasma induced arthritis, 202-211
permeability to plasma proteins, 560-570
prolonged immunoglobulin synthesis, 171
regeneration, histopathology of, 117-125
rheumatoid and regenerated, hydrolases in, 223-230
role of CTAP in inflammation, 41-54
Systemic lupus erythematosus
 antibodies to double-stranded RNA, 342-347
 antibodies to viral antigen, 1
 azathioprine in, 639-645
 cell mediated immunity during onset, 152
 cellular immunity to nuclear antigens, 163, 369
 chemotaxis in, 426
 choroidal plexus in, 148
 coagulation changes, 389
 complement fixation with platelets, 184
 Clq binding site, 382
 delayed hypersensitivity responses, 369
 Epstein-Barr virus antibody titers, 160
 fibrinogen degradation products in serum and urine, 267-275
 gonococcal arthritis, 557-559
 guidelines for cytotoxic drug therapy, 134
 hydralazine induced, 165
 IgG antinuclear subclasses and renal deposits, 276-282
 IgG protein binding Clq, 159
 immune responses in discordant twins, 373
 intra-articular C3 hypercatabolism, 410
 in vitro testing for cellular immunity to denatured DNA, 401
 low dose cyclophosphamide, 189

- lupus nephritis in children, histology and clinical course**, 170
lymphocyte lysis by complement, 414, 733-739
lymphocytotoxic antibodies, 149, 373-374
lysosomal antigen and antibody, 369
paramyxovirus-like structures and tissue fixed immunoglobulins, 421
reactions with histone fractions and histone-DNA complexes, 485-492
release of DNA antigen, 259-266
rheumatoid factor in, 147
rheumatoid factor precipitation of DNA-anti-DNA, 161
serum and CSF complement and autoantibodies, 180
soluble nuclear RNA protein, 412
thymectomy, 391-392
virus antibody studies, 180
- Tetracycline**
 in RA, 727-731, 788
 in septic arthritis, 96-104
- Thermography**, 387
- Thiotepa, intra-articular**, 212-222
- Thrombophlebitis, differentiation from dissecting popliteal cyst**, 591-598
- Thumb, intra-articular thiotepe in joint**, 212-222
- Thymectomy, thymus recurrence after**, 391
- Thyroiditis, allergic**, 191
- Toes, joint involvement**, 291-318
- Toxoplasma fluorescent antibody**, 149
- Transplant, renal, serologic changes**, 259-266
- Triamcinolone hexacetonide intra-articularly**, 383
- Triamcinolone inhibition of lymphocyte and joint fluid cytotoxin**, 180
- Tryptophan metabolism**, 167
- Tubercle bacillus enhanced cell migration**, 408
- Tuberculous arthritis**, 151
- Twins, discordant for SLE**, 372
- Ulcers in systemic scleroderma**, 184
- Ulnar styloid erosions**, 422
- Urate crystals**
 effect of colchicine on phagocytosis, 189
- Uric acid**
 defective renal excretion in Filipinos, 721-726
 excretion and urine flow rate, 158
 excretion, effect of Ipanoic acid on, 180-181
 hyperuricemia in American Samoans, 283-285
 renal handling, 380
- Uricase, oxonate inhibition**, 394
- Urine**
 flow rate and uric acid excretion, 158
 glycosylamino acids, 393
- Vasculitis**
 acute flare in hypocomplementemia, 231-237
 cyclophosphamide in, 414
 disseminated, methotrexate in, 175
 7S IgM in RA, 184
 morphology of synovium, 401
 RA, 650-665
- Vasoconstriction, cold induced**, 380, 381
- Venograms, study of arthroplasty of knee**, 376
- Villonodular synovitis**, 784-787
- Wax D**
 delayed skin reactivity, 395
 enhanced in vitro cell migration, 408
- Wegener's granulomatosis**
 cyclophosphamide in, 408
 methotrexate in, 175
- Wrist**
 scoring radiologic abnormalities, 706-713
- Xylosylserine levels in RA**, 393
- Yakima Indians, RA in**, 423
- Yttrium, intra-articular, radioactive**
 in RA, 399
 preparation and distribution in rabbits, 399
- Zymogen, collagenase in tadpole**, 388

EX

10